Biotech Series A Investors & VC Firms
1626 firms in this list, with a median first check of $500K. 369 of them lead rounds. Generated from verified public data and updated continuously.
Avego BioScience Capital
AlpharettaSeries A–Late Stage
2 people
Highlight Capital
NanjinSeed–Series B
1 person
Oita Venture Capital
OitaPre-Seed–Growth
1 person
Criteria Bio Ventures
BarcelonaSeed–Series B
7 people
Nourish Ventures
Seed–Series B
10 people
Nucleus Adventure Capital
New YorkPre-Seed–Series A
7 people
QC·VENTURES
ViennaSeed–Late Stage$216K – $4.3M
7 people
Cure Kids Ventures
AucklandSeed–Series A
6 people
Red Bear Angels
IthacaSeed–Series A$100K – $1M
3 people
Zypsy Capital
San FranciscoSeed–Series A$50K – $400K
3 people
Development Bank of Wales
CardiffSeed–Series A$12.7K – $12.7M
10 people
New Leaf Venture Partners
New YorkSeed–Series B
7 people
Shah Family Office
Seed–Growth
8 people
Vespucci Partners
BudapestSeed–Series A$648K – $4.9M
5 people
Deep Insight
Tel AvivPre-Seed–Late Stage
6 people
Cycad Group LLC
Santa BarbaraSeed–Late Stage
4 people
Moore Venture Partners
San DiegoSeed–Series A
5 people
CLI Ventures
Palo AltoSeed–Late Stage
6 people
Newpath Partners
BostonSeed–Series A$50K – $10M
3 people
Simpact Ventures
WarszawaPre-Seed–Series A$500K – $2M
6 people
Claremont Creek Ventures
OaklandSeed–Late Stage$500K – $3M
5 people
Jelix Ventures
SydneyPre-Seed–Series A
5 people
Med-Fine Capital
ShanghaiSeed–Series A
8 people
MSA Capital
Grand CaymanPre-Seed–Late Stage
6 people
Related lists
Series A Investors & VC Firms (7325)Series A Investors & VC Firms in North America (4219)Series A Investors & VC Firms in United States (3838)AI & Machine Learning Series A Investors & VC Firms (2601)SaaS Series A Investors & VC Firms (2590)Biotech Investors & VC Firms (2475)Series A Investors & VC Firms in Europe (2383)Fintech Series A Investors & VC Firms (2349)Healthtech Series A Investors & VC Firms (2309)Enterprise Software Series A Investors & VC Firms (2264)
Data sourced from public filings and firms' own websites — see our methodology.
















































































